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AbsTrACT
background The control of malaria in pregnancy (MiP) in 
India relies on testing women who present with symptoms 
or signs suggestive of malaria. We hypothesised that 
intermittent screening and treatment for malaria at each 
antenatal care visit (ISTp) would improve on this approach 
and reduce the adverse effects of MiP.
Methods A cluster randomised controlled trial comparing 
ISTp versus passive case detection (PCD) was conducted 
in Jharkhand state. Pregnant women of all parities with a 
gestational age of 18–28 weeks were enrolled. Women in 
the ISTp group were screened with a rapid diagnostic test 
(RDT) for malaria at each antenatal clinic visit and those in 
the PCD group were screened only if they had symptoms 
or signs suggestive of malaria. All RDT positive women 
were treated with artesunate/sulfadoxine–pyrimethamine. 
The primary endpoint was placental malaria, determined 
by placental histology, and the key secondary endpoints 
were birth weight, gestational age, vital status of the 
newborn baby and maternal anaemia.
results Between April 2012 and September 2015, 6868 
women were enrolled; 3300 in 46 ISTp clusters and 3568 
in 41 PCD clusters. In the ISTp arm, 4.9% of women were 
tested malaria positive and 0.6% in the PCD arm. There 
was no difference in the prevalence of placental malaria in 
the ISTp (87/1454, 6.0%) and PCD (65/1560, 4.2%) groups 
(6.0% vs 4.2%; OR 1.34, 95% CI 0.78 to 2.29, p=0.29) or 
in any of the secondary endpoints.
Conclusion ISTp detected more infections than PCD, but 
monthly ISTp with the current generation of RDT is unlikely 
to reduce placental malaria or impact on pregnancy 
outcomes. ISTp trials with more sensitive point-of-care 
diagnostic tests are needed.
InTroduCTIon
Malaria in pregnancy (MiP) is a major public 
health problem, contributing substantially 
to morbidity and mortality among pregnant 
women, developing fetuses and newborn 
babies in endemic areas.1 2 For the control of 
MiP, the WHO recommends effective treat-
ment, insecticide-treated bed nets (ITNs) 
and, in areas of moderate-to-high malaria 
transmission of sub-Saharan Africa, intermit-
tent preventive treatment with sulfadoxine–
pyrimethamine (IPTp-SP).3 IPTp-SP is given 
at each antenatal clinic (ANC) attendance 
after the first trimester, regardless of whether 
the recipient is infected with malaria or not. In 
low transmission settings, the use of IPTp-SP 
is questionable because the benefit/risk 
ratio of this intervention is likely to be low.4 
Key questions
What is already known?
 ► In low malaria transmission areas, testing pregnant 
women for malaria when they present with clinical 
symptoms (passive case detection (PCD) is the stan-
dard of care.
 ► In high malaria transmission areas, intermittent pre-
ventive treatment with sulfadoxine–pyrimethamine 
(IPT-SP) during monthly antenatal visits is the stan-
dard of care to reduce the consequences of malaria 
in pregnancy (MiP).
 ► It has been shown that intermittent screening with a 
rapid diagnostic test and treatment for malaria (ISTp) 
during antenatal visits is not inferior to IPT-SP.
What are the new findings?
 ► In a low transmission area in India, 70% of MiP was 
asymptomatic and ISTp detected more cases of MiP 
than PCD (4.9% vs 0.6%, p<0.001), but had no im-
pact on the risk of placental malaria or other adverse 
birth outcomes.
What do the new findings imply?
 ► Given that the majority of women infected with ma-
laria remain asymptomatic, ISTp during antenatal 
care could be considered in low transmission areas 
in India.
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In such areas, intermittent screening for malaria during 
antenatal visits using a rapid diagnostic test (RDT) and 
treating test-positive women with an effective antimalarial 
drug (ISTp) is a potential alternative option.5 6
In India, malaria transmission is relatively low and 
varies markedly between different ecological settings.7 
A study conducted in the eastern state of Jharkhand in 
2007 showed that placental parasitaemia, measured by 
RDT or placental smear microscopy, ranged from 0.8% 
in urban areas to 3.6% in rural areas. However, it is esti-
mated that 28.2 million pregnancies are at risk of Plas-
modium falciparum (Pf) malaria annually in India, and 
thus even a low prevalence can translate into substantial 
mortality and morbidity.8 Especially pregnant women 
from tribal populations and residents of forested hilly 
areas are known to be at higher risk of infection.9 The 
current national policy in India for the control of MiP 
is to test pregnant women who present with symptoms 
or signs suggestive of malaria with a blood slide and to 
treat confirmed cases using quinine in the first trimester 
and artesunate (AS)+SP or artemether+lumefantrine in 
the second or third trimester. The use of a long-lasting 
insecticide-treated net (LLIN) during pregnancy is 
recommended in high-risk areas, but there is no specific 
distribution system for LLINs linked with antenatal care 
services. The effectiveness of the current policy of passive 
case detection (PCD) of MiP in low transmission settings 
is unknown. We hypothesised that ISTp would be more 
effective than PCD in detecting MiP and that effective 
treatment of infected individuals would reduce the risk 
of placental malaria and adverse birth outcomes. In this 
paper, we report a study that evaluated the effectiveness 
of ISTp delivered through the routine antenatal care 
system in a moderate-to-low transmission setting in India.
MeTHods
study design
This was a two-arm, cluster randomised controlled trial 
that compared ISTp versus the current policy of PCD 
for malaria during antenatal care visits. The primary 
endpoint of the trial was placental malaria and the 
secondary endpoints were low birth weight, adverse fetal 
birth outcomes and maternal anaemia. The unit of rando-
misation was sub-health centres (SHC). Women were 
assigned to the ISTp arm or the PCD arm depending on 
the allocation of the SHC, where they attended ANC.
study area and population
The study was conducted in Jharkhand state, India, in 
an area surrounded by forest, where malaria transmis-
sion peaks during the rainy season from June to October. 
The study was implemented within the primary health-
care delivery system in four subdistricts, two from Gumla 
district (Kamdara and Basia) and two from Simdega 
district (Bano and Kolebira). The population in each of 
the four subdistricts ranged from 63 775 to 80 731.10 Each 
subdistrict has one primary health centre (PHC) and 
several SHCs, those have at least one auxiliary midwife 
(ANM) who provides antenatal care. In Basia subdistrict, 
there is a government hospital and the St. Ursula mission 
hospital, which served as the study hospital. Delivery 
services are available in all PHCs and in approximately 
75% of SHCs. Emergency obstetric care, including 
caesarean section, is provided in the government and 
mission hospital in Basia.
sample size and randomisation
During an observational study done in 2007, 4% of 
women attending ANC at St. Ursula mission hospital had 
peripheral malaria parasitaemia.11 Assuming the risk of 
placental malaria would be higher than that of periph-
eral parasitaemia, we expected that 7.5% of women in the 
PCD arm would have placental malaria, and we hypothe-
sised that ISTp would reduce the risk of placental malaria 
by 25%. In order to detect a 25% reduction in the risk 
of placental malaria with 80% power, a two-sided alpha 
of 0.05 and a design effect of 1.25, the study needed 31 
clusters per arm and 100 women per cluster, total 6200 
women. Women attending an individual SHC for ante-
natal care comprised a cluster. As there were 80 SHCs in 
the four study subdistricts and it was uncertain whether 
it would be possible to enrol 100 women per cluster in 
2 years, we randomised all 80 SHCs (40:40). We stratified 
the SHCs by subdistricts and then assigned numbers to 
randomise them to two groups.
As the enrolment rate was slower than expected, and 
eight SHCs had to be closed due to security concerns, 
we replaced them with 15 maternal and children care 
centres (Anganwadi centres) in the subdistrict of Bano 
in July 2012.
Trial procedures
All staff who provided antenatal and delivery care in 
the study SHCs, PHCs and hospital, and the project 
field staff were trained to follow trial standard operating 
procedures and to complete study case record forms. 
All eligible pregnant women attending at an ANC at the 
study SHCs were enrolled in the study after informed 
consent had been obtained. Pregnant women of all pari-
ties with a gestational age of 18–28 weeks were eligible for 
enrolment. Pregnant women with a chronic illness were 
excluded. All study participants were given free health 
and delivery services at the study hospital, PHCs or SHCs.
At enrolment, women in both groups received routine 
antenatal care. A finger prick blood sample was taken 
for the assessment of haemoglobin (HemoCue, Angel-
holm, Sweden) and for the collection of a filter paper 
sample. Syphilis and HIV testing were only done if part of 
routine ANC. In the ISTp group, all women had an RDT 
(SD Bioline Malaria Ag Pf/Pv (histidine-rich-protein 2 
(HRP-2)/plasmodium lactate dehydrogenase (pLDH), 
www. Standardia. com)), a blood smear and filter paper 
sample (Whatman Grade 3 Chr) collected, irrespective 
of a history of fever, at each ANC attendance. In the 
PCD group, only women with a history of fever within 
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Figure 1:  Consort Chart  
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Figure 1 Consort chart. ANC, antenatal clinic; IST, 
intermittent screening and treatment; PCD, passive case 
detection.
Table 1 Comparison of baseline characteristics between 
the two study groups
ISTp PCD
N (%) N (%)
Number of clusters 46 41
Number of women 3300 3568
Women per cluster
  Median (range) 93 (6–224) 92 (10–264)
Age group, years
  <20 170 (5.2) 176 (4.9)
  20–24 1326 (40.2) 1405 (39.3)
  25–29 1159 (35.2) 1241 (34.8)
  30+ 644 (19.5) 746 (21.0)
Gravidity
  Primi- 1218 (36.9) 1334 (37.4)
  Secondi- 955 (28.9) 973 (27.3)
  Multi- 1127 (34.1) 1261 (35.4)
Education
  None 977 (29.6%) 976 (27.4)
  Primary 1128 (34.2) 1253 (35.1)
  Secondary 706 (21.4) 771 (21.7)
  Higher 488 (14.8) 567 (15.9)
Slept under net previous 
night
  Yes 2368 (71.9) 2860 (80.3)
Slept under an ITN 
previous night
  Yes 338 (13.8) 400 (13.7)
Socioeconomic quintile
  Poorest 670 (20.4) 700 (19.7)
  2 718 (21.8) 696 (19.6)
  3 669 (20.6) 657 (18.5)
  4 679 (20.4) 694 (19.5)
  Least poor 556 (16.9) 810 (22.8)
Haemoglobin (g/L)
  <70 34 (1.0) 27 (0.76)
  70 to <110 2800 (84.9) 2912 (81.8)
  ≥110 465 (14.1) 623 (17.5)
History of fever 
(<48 hours) or 
temperature>37.5°C
  Yes 279 (8.5) 182 (5.1)
  RDT done 3163 (95.8) 108 (3.0)
  RDT positive 101 (3.2) 10 (9.3)
RDT species 
specification
  P. falciparum 84 (2.7) 7 (6.5)
  P. vivax 9 (0.3) 2 (2.0)
Continued
ISTp PCD
N (%) N (%)
  Mixed infection (Pf+Pv) 8 (0.3) 1 (0.9)
PCR done 2620 (79.4) 2706 (75.8)
PCR positive 155 (5.9) 114 (4.2)
Symptomatic malaria* 30 (29.7) 10 (100.0)
*RDT positive plus history of fever (<48 hours) or 
temperature>37.5°C.
ISTp, intermittent screening and treatment during pregnancy; ITN, 
insecticide-treated bed net; P., Plasmodium; PCD, passive case 
detection; Pf, Plasmodium falciparum; Pv, Plasmodium vivax; RDT, 
rapid diagnostic test.
Table 1 Continued
the past 48 hours or an axillary temperature >37.5°C were 
tested for malaria with an RDT and had a blood slide and 
filter paper sample collected. Women who had a positive 
RDT for malaria were treated with AS+SP according to 
the national treatment guidelines. The treatment was 
provided by the ANMs but was not supervised. Women 
in both groups were advised to attend ANCs regularly 
every month, and to attend a study health facility if they 
had any illness in between scheduled ANC visits. In both 
groups, if a woman presented with a history of fever in 
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Table 2 Prevalence of placental malaria among women who had an institutional delivery within the study area
IST PCD Adjusted
OR* 95% CI P valueN (%) N (%)
Total number of women 1469 1584 –
Placental blood RDT done 1405 (95.6) 1540 (97.2) –
Placental blood RDT result
P. falciparum 28 (2.0) 21 (1.4) –
P. vivax 2 (0.1) 6 (0.4)
Mixed infection (Pf+Pv) 2 (0.1) 4 (0.3)
Placental histology done 1454 (98.9) 1560 (98.5)
Any placental malaria 87 (6.0) 65 (4.2) 1.34 0.78 to 2.29 0.29
Active infection 30 (2.1) 27 (1.7) 1.03 0.51 to 2.10 0.93
  Acute infection 11 (0.8) 8 (0.5) 1.16 0.41 to 3.26 0.78
  Chronic infection 19 (1.3) 19 (1.2) 1.04 0.43 to 2.51 0.93
Past infection 57 (2.4) 38 (3.9) 1.54 0.88 to 2.68 0.12
*All models were adjusted for gravidity, use of a net/ITN, severe anaemia at enrolment, fever at enrolment and socioeconomic status.
IST, intermittent screening and treatment; ITN, insecticide-treated bed net; P., Plasmodium; PCD, passive case detection; Pf, Plasmodium 
falciparum; Pv, Plasmodium vivax; RDT, rapid diagnostic test.
between scheduled ANC visits, they had an RDT done, 
blood slide and filter paper sample collected and, if the 
RDT was positive, they were treated with AS+SP.
At delivery, birth outcomes, birth weight, and the 
Ballard score of the newborn were assessed, and blood 
samples for haemoglobin, microscopy and PCR were 
collected from both groups of women. A placental biopsy 
and blood smear were taken from all women who deliv-
ered in the study hospital or had an institutional delivery 
within the study area. If a woman delivered at home, or 
in an institution other than the study health facilities, 
delivery outcomes were assessed ideally within 7 days 
of delivery. Study participants were followed once every 
2 months up to 6 months postpartum to assess the health 
status of the mother and her child. A verbal autopsy (VA) 
was done for all maternal deaths using the WHO 2016 
VA questionnaire12 and the cause of death was assigned 
using the InterVA4 algorithm.13
Laboratory methods
Blood slides were fixed and stained with Giemsa. All 
peripheral and placental blood slides were read twice 
by study laboratory technicians. For quality control of 
microscopy, experienced laboratory technicians from the 
National Institute of Malaria Research, Rourkela Field 
Station, re-read all slides reported positive by the study 
laboratory technicians and 50% of negative slides in year 
1, 30% in year 2 and 10% in year 3.
Placental biopsies (2.5×2.5×1 cm) were collected by 
ANMs at the time of delivery, stored in 10% buffered 
formalin containers and taken to the study hospital. On a 
weekly basis, the biopsies were taken to a private pathology 
laboratory in Ranchi where they were processed into 
paraffin tissue blocks. From each block, a set of two slides 
was prepared, one H&E and one Giemsa stained. The 
slides were read by two pathologists (SS and PB) based at 
the Ispat General Hospital, Rourkela, who were trained 
on-site by a malaria histopathology expert (AM) from the 
Centers for Disease Control, Atlanta. All histopatholog-
ical slides were read by both pathologists and slides with 
discordant results were read again by both pathologists to 
reach a final diagnosis by consensus. The expert pathol-
ogist read 100% of slides that were classified as placental 
malaria positive and 30% of slides classified as negative 
by the site pathologists. In case of discordant readings, 
the expert’s opinion was deemed to be the final reading. 
If malaria parasites were seen in the biopsy, it was classi-
fied as active placental malaria. Active placental malaria 
was further classified as acute if there were no malaria 
pigments in fibrin and chronic if there were malaria 
pigments in fibrin. If there were no parasites, but there 
were malaria pigments in fibrin, the sample was classified 
as past placental malaria.14
Filter paper samples taken at enrolment and at delivery 
(peripheral and placental blood) were tested by PCR in 
a laboratory in Bangalore, India (Ecron Acunova). DNA 
extraction was done using the QIAamp Blood DNA Mini 
Extraction Kit from Qiagen. Real-time (RT) PCR assays, 
using the Taqman principle, were done with the Genome 
RT PCR Malaria Kit from Genome Diagnostics.
data management and analysis
Data were double entered and verified using the EpiData 
V.3.1 software ( www. epidata. dk). Data processing and 
analysis were done using the statistical software package 
STATA V.IC14.0.
All women who were enrolled and for whom informa-
tion on pregnancy outcomes was available were included 
in the analysis (intention-to-treat analysis). Principal 
components analysis was used to obtain a socioeconomic 
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Table 3 Prevalence of RDT-positive malaria at ANC visits 
2, 3 and 4
IST PCD
P value*N (%) N (%)
ANC visit 2
  Total number of women 1776 2391
  RDT done 1663 (93.6) 30 (1.3) <0.001
  RDT result
  P. falciparum 24 (1.4) 1 (3.3)
  P. vivax 8 (0.5) 4 (13.3)
  Mixed infection (Pf+Pv)
  Symptomatic malaria†
5 (0.3)
10 (27.0)
0
5 (100.0)
ANC visit 3
  Total number of women 930 1507
  RDT done 856 (92.3) 23 (1.5) <0.001
  RDT result
  P. falciparum 12 (1.4) 1 (4.3)
  P. vivax 4 (0.5) 7 (30.4)
  Mixed infection (Pf+Pv)
  Symptomatic malaria†
2 (0.2)
6 (33.3)
0
8 (100.0)
ANC visit 4
  Total number of women 409 651
  RDT done 394 (96.3) 0 <0.001
  RDT result –
  P. falciparum 3 (0.8) 0
  P. vivax 1 (0.3) 0
  Mixed infection (Pf+Pv)
  Symptomatic malaria†
3 (0.8)
4 (57.1)
0
0
*Pearson’s design-based test.
†RDT positive plus history of fever (<48 hours) or 
temperature>37.5°C.
ANC, antenatal clinic; IST, intermittent screening and treatment; 
P., Plasmodium; PCD, passive case detection; Pf, Plasmodium 
falciparum; Pv, Plasmodium vivax; RDT, rapid diagnostic test.
score based on household characteristics and assets. This 
was then divided into quintiles to create household socio-
economic groups. Baseline characteristics at enrolment 
were summarised and compared between the ISTp and 
PCD groups.
Pearson’s design-based test was used to compare the 
prevalence of RDT, blood slide and PCR-positive malaria 
across study arms. To account for clustering by village 
in primary outcomes, a logistic random effects model 
was used to compare the odds of each outcome in the 
ISTp versus PCD groups. A quadrature check was applied 
to the model postestimation to assess the reliability of 
the model. An estimate of the between-cluster SD was 
obtained for each outcome from the models and assessed 
using a likelihood ratio test. Women’s characteristics and 
measurements at enrolment were compared for women 
who had a biopsy and those who did not using Pearson’s 
design-based test.
Patient and public involvement statement
The patients were not involved in the design, recruitment 
or conduct of the study. The results were disseminated to 
all relevant stakeholders, including the trial participants.
resuLTs
study population
Between April 2012 and September 2014, we enrolled 
3300 women in 46 clusters in the ISTp group and 3568 
women in 41 clusters in the PCD group (figure 1). The 
total number of clusters and women in the two groups 
differed as some SHCs had to be closed due to secu-
rity concerns. The cluster size ranged from 6 to 224 in 
the ISTp group and from 10 to 264 in the PCD group 
(table 1). The median size of the clusters was, however, 
similar in the two groups (93 and 92 women per cluster 
in ISTp and PCD, respectively). The proportion of 
women who attended ANC visits 2 and 3 was overall low 
(61% and 35%) but even lower in the ISTp group than 
in the PCD group (54% vs 67% for visit 2 (p=0.01) and 
28% vs 42% for visit 3 (p=0.02)) (figure 1). However, 
the percentage of women who were seen at delivery was 
similar in each group (45%). Almost all women were seen 
at the final 6-month postpartum home visit (99.8%). The 
last delivery and postnatal follow-up took place in April 
and October 2015, respectively.
There were no significant differences in the distribu-
tion of age, gravidity, education, socioeconomic status 
and use of an ITN between the two trial groups (table 1). 
The proportion of women who reported a history of fever 
in the past 48 hours or temperature >37.5°C was slightly 
higher at enrolment in the ISTp group (8.5% vs 5.1%). 
The proportion of women who had received antimalarial 
treatment from the private sector at any time during their 
current pregnancy was high, 7.8% in the ISTp group and 
7.1% in the PCD group.
Prevalence of malaria at enrolment
At enrolment, 95.8% of women in the IST group were 
tested with an RDT and 3.2% were malaria positive; 2.7% 
had a Pf, 0.3% a P. vivax (Pv) and 0.3% a mixed infec-
tion (Pf/Pv) (table 1). According to national policy, RDT 
testing was restricted to those who had symptoms sugges-
tive of malaria in the PCD group and only 3% of women 
had an RDT done at enrolment; of those 6.5% were tested 
positive for Pf, 2% for Pv and 0.9% for a mixed infection 
(Pf/Pv). The proportion of women who were tested with 
PCR at enrolment was comparable between the groups 
(79.4% vs 75.8%) and the prevalence of PCR positive 
malaria did not differ between the two groups (5.9% vs 
4.2%, p=0.30) (table 1). Reasons for women having no 
PCR result at enrolment include that the sample was 
either not collected or that the dried blood spots were 
too small for the amount needed for DNA extraction.
Primary endpoint—placental malaria
Placental biopsies were available from 1454 (44.0%) 
women from the ISTp group and from 1560 (43.7%) 
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Table 4 Delivery and birth outcomes
IST PCD
Adjusted OR* 95% CI P valuen/N (%) n/N (%)
Total number of women 3300 3568
Birth weight†
  ≥2.5 kg 2590/2971 (87.2) 2771/3177 (87.2)
  <2.5 kg 381/2971 (12.8) 406/3177 (12.8) 1.07 0.86 to 1.34 0.56
Gestational age at birth†
  Preterm‡ 515/3181 (16.2) 645/3432 (18.8) 1.31 0.81 to 2.10 0.27
  Miscarriage§ or stillborn 106/3240 (3.3) 107/3452 (3.1) 1.12 0.72 to 1.74 0.62
  Died<24 hours 30/3131 (0.96) 28/3351 (0.84) 1.44 0.45 to 4.62 0.54
  Died<1 week 49/3133 (1.6) 46/3406 (1.4) 0.96 0.51 to 1.81 0.89
Maternal Hb status†
  Hb≥11 g/dL 186 (12.6) 236 (14.7)
  Hb<11 g/dL 1278 (86.7) 1347 (84.1) 1.17 0.83 to 3.91 0.14
  Hb<7 g/dL 25 (0.7) 19 (1.1) 1.71 0.64 to 4.54 0.28
Maternal peripheral† blood
  RDT positive 34 (2.4) 25 (1.6) 1.30 0.67 to 2.52 0.44
  PCR positive 62 (4.6) 52 (3.7) 1.06 0.59 to 1.90 0.84
*All models were adjusted for gravidity, use of a net/ITN, severe anaemia at enrolment, fever at enrolment and socioeconomic status.
†The total number of babies for each outcome varies due to missing values. Hb was only measured at delivery.
‡Gestational age<37 weeks.
§Spontaneous expulsion of fetus before 24 weeks of gestation.
Hb, haemoglobin; IST, intermittent screening and treatment; ITN, insecticide-treated bed net; PCD, passive case detection; RDT, rapid 
diagnostic test.
from the PCD group. The proportion of women with 
active or past placental malaria was lower than expected 
in the study cohort overall (5.0%, 152/3014). There was 
no statistically significant difference in the proportion 
of women with any placental malaria between the two 
groups (6% vs 4.2%) or the proportion of women with 
active (2.1% vs 1.7%) or past (2.4% vs 3.9%) placental 
malaria (table 2). The ORs of active and past placental 
malaria in the IST group compared with the PCD group 
were 1.03 (95% CI 0.51 to 2.10, p=0.93) and 1.54 (95% 
CI 0.88 to 2.68, p=0.12), respectively. There were 87 cases 
of placental malaria in the IST group (table 2). However, 
only 10 of these cases had a positive RDT anytime during 
the ANC visits. Thus, the sensitivity of the RDT to detect 
placental malaria was 11.5% (10/87).
The risk of MiP varied substantially between clusters. 
The intracluster correlation coefficient for any placental 
malaria was 0.177 (95% CI 0.066 to 0.395). The number 
of placental malaria infections ranged from 0 to 9 per 
cluster; 29 clusters (14 ISTp and 15 PCD clusters) had no 
cases of placental malaria and five clusters had >7 cases of 
placental malaria (3 ISTp and 2 PCD clusters). However, 
the high and low placental malaria clusters were distrib-
uted equally between the two groups.
secondary endpoints
The proportions of women in the ISTp group tested with 
an RDT during ANC visits 2, 3 and 4 were 1663/1776 
(93.6%), 856/930 (92.3%) and 394/409 (96.3%), 
respectively, and among those tested, 2.2%, 2.1% and 
1.7%, respectively, were positive for malaria (table 3). In 
the PCD group, the proportions of women suspected to 
have malaria and tested with an RDT at ANC visits 2 and 3 
were 30/2391 (1.3 %) and 23/1507 (1.5%), respectively, 
and among those tested, 16.7% and 34.8%, respectively, 
were positive for malaria; no women had an RDT at the 
ANC visit 4.
The proportion of women who had RDT-positive 
malaria at least once during ANC and treated with 
AS+SP across all ANC visits was significantly higher in the 
ISTp arm 4.9% (163/3300) than in the PCD arm 0.6% 
(23/3568) (p<0.001).
Of all women tested RDT positive, 71% (132/186) had 
Pf malaria, 19% (35/186) Pv malaria and 10% (19/186) 
a mixed infection (Pf/Pv).
There was no statistically significant difference in low 
birth weight, preterm delivery, stillbirth or early neonatal 
death between the two groups (table 4).
safety endpoints
There were 27 maternal deaths (death during preg-
nancy, delivery or within 42 days of delivery); 12 in the 
ISTp group and 15 in the PCD group (table 5). There 
were four maternal deaths attributable to malaria (two 
in each group) determined by verbal autopsy. However, 
there were no cases of severe malaria admitted to the 
study hospital.
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Table 5 Distribution of causes of maternal deaths in the 
two comparison groups
ISTp PCD
N (%) N (%)
Number of maternal deaths 12 15
Causes of death
  Malaria 2 (16.7) 2 (13.3)
  Pneumonia 1 (8.3) 2 (13.3)
  Anaemia 0 2 (13.3)
  HIV 1 (8.3) 1 (6.6)
  Pulmonary TB 1 (8.3) 0
  Sepsis 0 1 (6.6)
  Meningitis 1 (8.3) 0
  Pregnancy-induced 
hypertension/eclampsia
0 4 (26.6)
  Other cardiac diseases 0 2 (13.3)
  Epilepsy 1 (8.3) 0
  Cirrhosis 1 (8.3) 0
  Reproductive tract neoplasm 1 (8.3) 0
  Obstetric haemorrhage 1 (8.3) 1 (6.6)
  Suicide 1 (8.3) 0
  Undetermined 1 (8.3) 0
ISTp, intermittent screening and treatment during pregnancy; 
PCD, passive case detection; TB, tuberculosis.
dIsCussIon
ISTp detected more women with MiP compared with the 
current policy of PCD. However, ISTp did not reduce 
the risk of placental malaria or adverse birth outcomes 
compared with PCD. The possible reasons for ISTp not 
having an effect on placental malaria are: (i) only 28.2% 
of women were tested with an RDT at least three times 
during pregnancy in the IST group as they did not attend 
ANC frequently, (ii) the current generation of RDTs 
does not detect the majority of cases of placental malaria 
and (iii) a high proportion of women from both arms 
were treated with antimalarials from the private health 
sector. The most recent National Family Health Survey 
conducted in 2015–2016 reported that only 24.7% of 
mothers in rural Jharkhand had at least four ANC visits 
and 5.5% received full antenatal care, defined as mothers 
who had at least four ANC visits, one tetanus toxoid 
injection and at least 100 days of iron–folic acid tablets 
or syrup intake.15 The strengthening of ANC services 
would improve the effectiveness of interventions deliv-
ered as part of the existing ANC services and support 
the achievement of universal coverage. As part of ANC, a 
formal bed net distribution system for pregnant women 
and children would support the control of MiP. In our 
cohort, only 13.8% of pregnant women slept under an 
ITN the previous night.
The sensitivity of RDTs in pregnancy is lower than in 
non-pregnant populations.16 17 In our study, the observed 
sensitivity of RDTs to detect histology-confirmed 
placental malaria was 11.5%, similar to the sensitivity of 
10% reported from Indonesia18 but lower to the sensi-
tivity reported from Africa (73%, 95% CI 64 to 81).19
In low malaria transmission settings, where both symp-
tomatic and asymptomatic patients should be identi-
fied and treated, the conventional RDTs miss important 
proportions of infections. New combination, highly 
sensitive RDTs able to identify all infected individuals, 
will support countries implementing active case detec-
tion strategies,20 but their use and added benefit for 
malaria case management in pregnancy will need to be 
assessed.21 The high maternal mortality ratio (437/100 
000) and perinatal mortality rate (39.3/1000) observed 
in the study cohort suggest that the risk factors for 
adverse birth outcomes in this community are multifac-
torial, including a weak health system. Health systems 
challenges in Jharkhand also include insufficient access 
to care and potential treatment effects might be diluted 
by the high background rates of care seeking and treat-
ment from the private sector.22 23
The prevalence of placental malaria in this study 
(4.2%) was lower than expected but is comparable to 
the prevalence of placental parasitaemia detected by 
impression smear (3.6%) in the study area in 2007.11 
Placental biopsy samples were available from <50% of the 
study participants because it was not feasible to collect 
placental samples when a woman delivered at home, in a 
private health facility, in a facility outside the study area 
or had an abortion. However, there was no difference in 
the baseline characteristics between the women with and 
without placental biopsy samples (online supplemen-
tary table 1). Thus, missing placental biopsy samples is 
unlikely to bias the comparison between the groups.
In Africa, the proportion of women detected to have 
malaria by routine screening is much higher on first 
attendance at an ANC than on subsequent visits,5 making 
single screening at first ANC attendance a potentially 
useful approach to malaria control. This was not the case 
in this study, where RDT-positive malaria ranged 2%–3% 
at all ANC visits. ISTp was shown to be inferior to IPTp 
with SP in several African settings.6 However, in areas with 
perennial transmission and SP resistance, in east Africa, it 
was shown that IPTp-SP was superior to ISTp in reducing 
adverse birth outcomes.24
A cross-sectional survey of children aged <5 years in the 
study area in 2014 showed a malaria prevalence of 5.2%, 
6.4% and 8.5% by blood slide, RDT and PCR, respec-
tively. Even though malaria transmission is very low in 
the study setting, the majority of women with MiP were 
asymptomatic, suggesting that PCD does not appropri-
ately control MiP. RDT-positive malaria ranged 2%–3% 
at all ANC visits in this low transmission setting and ISTp 
implemented through the routine ANC system was able 
to detect more malaria cases compared with PCD. PCD 
misses detection of a significant proportion of pregnant 
women carrying parasite and screening as part of ANC 
could be a useful approach to detect and treat MiP. 
However, with the current generation of RDTs and low 
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attendance of repeat ANC visits, monthly ISTp is unlikely 
to have a major impact on the risk of placental malaria 
or adverse pregnancy outcomes relative to the existing 
strategy that relies largely on PCD.
This study has several limitations: (i) the prevalence of 
MiP was lower than expected, (ii) the cluster sizes varied 
considerably and (iii) a large proportion of placental 
samples could not be collected. Despite these limitations, 
the results allow to conclude that intermittent screening 
and treatment during ANC is a useful approach to detect 
and treat MiP. Any potential ISTp screening strategy in 
India would need to consider the individual risk of Pf 
and/or Pv infection. Screening of pregnant women at 
their first ANC visit and re-testing only positive cases at 
subsequent visits would be a possible approach. Women 
tested positive are also more likely to return for repeat 
ANC visits. The feasibility and cost implications, espe-
cially in combination with conventional or new highly 
sensitive RDTs, would, however, need to be assessed.
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